ANGIODYNAMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.03 USD | -3.67% |
|
-4.74% | -23.09% |
| Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
| Apr. 05 | Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target | MT |
Financials (USD)
| Sales 2024 * | 287M | Sales 2025 * | 287M | Capitalization | 251M |
|---|---|---|---|---|---|
| Net income 2024 * | -194M | Net income 2025 * | -43M | EV / Sales 2024 * | 0.87 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.87 x |
| P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-7.03
x | Employees | 815 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on AngioDynamics, Inc.
More recommendations
More press releases
| 1 day | -3.67% | ||
| 1 week | -7.37% | ||
| Current month | +2.73% | ||
| 1 month | +14.42% | ||
| 3 months | +0.67% | ||
| 6 months | -9.05% | ||
| Current year | -23.09% |
1 week
5.99
6.55
1 month
5.267.52
Current year
5.268.25
1 year
5.2611.38
3 years
5.2632.00
5 years
5.2632.00
10 years
5.2632.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Clemmer
CEO | Chief Executive Officer | 60 | 16-03-31 |
| Director of Finance/CFO | 49 | 08-05-31 | |
Juan Serna
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jan Reed
BRD | Director/Board Member | 64 | 16-11-08 |
Howard Donnelly
CHM | Chairman | 63 | 04-02-29 |
Wesley Johnson
BRD | Director/Board Member | 65 | 07-01-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 27 M€ | -4.16% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 6.26 | 0.00% | 336,227 |
| 24-04-19 | 6.26 | +2.29% | 479,291 |
| 24-04-18 | 6.12 | -3.32% | 806,891 |
| 24-04-17 | 6.33 | -2.76% | 490,691 |
| 24-04-16 | 6.51 | +3.17% | 514,506 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Calendar
2024-07-09
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.26
USD
Average target price
13.5
USD
Spread / Average Target
+115.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.09% | 251M | |
| -2.25% | 186B | |
| -1.32% | 107B | |
| -3.92% | 67.57B | |
| +7.99% | 50.7B | |
| +15.74% | 47.2B | |
| -0.45% | 39.72B | |
| +10.81% | 27.48B | |
| +2.34% | 25.65B | |
| +13.37% | 24.97B |
- Stock Market
- Equities
- ANGO Stock
